OOIR: Observatory of International Research

Papers

(The TQCC of Thoracic Cancer is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Curcumin induces ferroptosis in non‐small‐cell lung cancer via activating autophagy	141
Epidemiology of esophageal cancer in 2020 and projections to 2030 and 2040	103
Quercetin induces pro‐apoptotic autophagy via SIRT1/AMPK signaling pathway in human lung cancer cell lines A549 and H1299 in vitro	102
Immune microenvironment features and efficacy of PD‐1/PD‐L1 blockade in non‐small cell lung cancer patients with EGFR or HER2 exon 20 insertions	44
Tumor‐associated macrophages: An important player in breast cancer progression	42
Exosome‐derived miR‐210 involved in resistance to osimertinib and epithelial–mesenchymal transition in EGFR mutant non‐small cell lung cancer cells	33
Impact of concomitant medication on clinical outcomes in patients with advanced non‐small cell lung cancer treated with immune checkpoint inhibitors: A retrospective study	32
miR‐21‐5p/SMAD7 axis promotes the progress of lung cancer	32
Smoking status during first‐line immunotherapy and chemotherapy in NSCLC patients: A case–control matched analysis from a large multicenter study	31
CAR‐T cell therapy for lung cancer: Potential and perspective	31
Global burden of thyroid cancer and its attributable risk factors in 204 countries and territories from 1990 to 2019	30
Propofol suppresses lung cancer tumorigenesis by modulating the circ‐ERBB2/miR‐7‐5p/FOXM1 axis	30
Outcome and risk factor of immune‐related adverse events and pneumonitis in patients with advanced or postoperative recurrent non‐small cell lung cancer treated with immune checkpoint inhibitors	30
Lung cancer risk prediction models based on pulmonary nodules: A systematic review	28
KIF4A enhanced cell proliferation and migration via Hippo signaling and predicted a poor prognosis in esophageal squamous cell carcinoma	27
tRNA‐derived fragments: tRF‐Gly‐CCC‐046, tRF‐Tyr‐GTA‐010 and tRF‐Pro‐TGG‐001 as novel diagnostic biomarkers for breast cancer	26
Tumor‐educated platelet SNORD55 as a potential biomarker for the early diagnosis of non‐small cell lung cancer	26
Osimertinib combined with bevacizumab for leptomeningeal metastasis from EGFR‐mutation non‐small cell lung cancer: A phase II single‐arm prospective clinical trial	25
Identification of a novel anoikis‐related gene signature to predict prognosis and tumor microenvironment in lung adenocarcinoma	24
Survival and pretreatment prognostic factors for extensive‐stage small cell lung cancer: A comprehensive analysis of 358 patients	24
Plasma miR‐1247‐5p, miR‐301b‐3p and miR‐105‐5p as potential biomarkers for early diagnosis of non‐small cell lung cancer	24
Targeting the EMT transcription factor Snail overcomes resistance to osimertinib in EGFR‐mutant non‐small cell lung cancer	24
Robot‐assisted thoracic surgery versus video‐assisted thoracic surgery for treatment of patients with thymoma: A systematic review and meta‐analysis	24
A novel lncRNA‐miRNA‐mRNA competing endogenous RNA regulatory network in lung adenocarcinoma and kidney renal papillary cell carcinoma	24
Biglycan, tumor endothelial cell secreting proteoglycan, as possible biomarker for lung cancer	23

Clinical implication of minimal presence of solid or micropapillary subtype in early‐stage lung adenocarcinoma	23
Association between pretreatment neutrophil‐to‐lymphocyte ratio and immune‐related adverse events due to immune checkpoint inhibitors in patients with non‐small cell lung cancer	23
PIWI‐interacting RNAs are aberrantly expressed and may serve as novel biomarkers for diagnosis of lung adenocarcinoma	23
Tumor‐associated macrophages (TAMs)‐derived osteopontin (OPN) upregulatesPD‐L1expression and predicts poor prognosis in non‐small cell lung cancer (NSCLC)	23
Immune checkpoint inhibitor‐related adverse events in lung cancer: Real‐world incidence and management practices of 1905 patients in China	22
Clinical utility of the C‐reactive protein:albumin ratio in non‐small cell lung cancer patients treated with nivolumab	22
LncRNASGMS1‐AS1 regulates lung adenocarcinoma cell proliferation, migration, invasion, and EMT progression via miR‐106a‐5p/MYLI9 axis	22
Circulating cytokines associated with clinical outcomes in advanced non‐small cell lung cancer patients who received chemoimmunotherapy	22
Exosomal miR‐3180‐3p inhibits proliferation and metastasis of non‐small cell lung cancer by downregulating FOXP4	22
MiR‐205‐5p promotes lung cancer progression and is valuable for the diagnosis of lung cancer	21
LncRNA LINC00460: Function and mechanism in human cancer	21
Feasibility of next‐generation sequencing test for patients with advanced NSCLC in clinical practice	21
Differential diagnosis of lung cancer and benign lung lesion using salivary metabolites: A preliminary study	21
Anti‐PD1 versus anti‐PD‐L1 immunotherapy in first‐line therapy for advanced non‐small cell lung cancer: A systematic review and meta‐analysis	21
Identification of small proline‐rich protein 1B (SPRR1B) as a prognostically predictive biomarker for lung adenocarcinoma by integrative bioinformatic analysis	20
Electromagnetic navigation bronchoscopic localization versus percutaneous CT‐guided localization for thoracoscopic resection of small pulmonary nodules	20
Comprehensive genomic profiling of Brazilian non‐small cell lung cancer patients (GBOT 0118/LACOG0418)	20
Clinical outcomes and radiation pneumonitis after concurrent EGFR‐tyrosine kinase inhibitors and radiotherapy for unresectable stage III non‐small cell lung cancer	19
Short‐term local control after VATS segmentectomy and lobectomy for solid NSCLC of less than 2 cm	19
Prognostic factor analysis of patients with small cell lung cancer: Real‐world data from 988 patients	19
Real‐world efficacy of atezolizumab in non‐small cell lung cancer: A multicenter cohort study focused on performance status and retreatment after failure of anti‐PD‐1 antibody	19
Microwave ablation via a flexible catheter for the treatment of nonsurgical peripheral lung cancer: A pilot study	18
LncRNA FAM83A‐AS1 promotes lung adenocarcinoma progression by enhancing the pre‐mRNA stability of FAM83A	18
Liquid biopsies to distinguish malignant from benign pulmonary nodules	18
Overexpression of hsa_circ_0008274 inhibited the progression of lung adenocarcinoma by regulating HMGA2 via sponging miR‐578	18
Genomic characteristics of driver genes in Chinese patients with non‐small cell lung cancer	17
Silencing LINC01116 suppresses the development of lung adenocarcinoma via the AKT signaling pathway	17
Prognostic value of the geriatric nutritional risk index among patients with previously treated advanced non‐small cell lung cancer who subsequently underwent immunotherapy	17
Activity of tarloxotinib‐E in cells with EGFR exon‐20 insertion mutations and mechanisms of acquired resistance	17
Mediastinal “deep freeze”—transcarinal lymph node cryobiopsy	17
Comparison of ultrasound and mammography for early diagnosis of breast cancer among Chinese women with suspected breast lesions: A prospective trial	17
Exosomal circDNER enhances paclitaxel resistance and tumorigenicity of lung cancer via targeting miR‐139‐5p/ITGB8	17
ALKrearrangements as mechanisms of acquired resistance to osimertinib inEGFRmutant non‐small cell lung cancer	17
Effect of durvalumab on local control after concurrent chemoradiotherapy for locally advanced non‐small cell lung cancer in comparison with chemoradiotherapy alone	17
SHR‐1316, an anti‐PD‐L1 antibody, plus chemotherapy as the first‐line treatment for advanced esophageal squamous cell carcinoma: A multicentre, phase 2 study	17
Progress in three‐dimensional computed tomography reconstruction in anatomic pulmonary segmentectomy	17
Circulating microRNAs as indicators in the prediction of neoadjuvant chemotherapy response in luminal B breast cancer	16
miR‐223‐3p targets FBXW7 to promote epithelial‐mesenchymal transition and metastasis in breast cancer	16
Pre‐existing interstitial lung disease does not affect prognosis in non‐small cell lung cancer patients with PD‐L1 expression ≥50% on first‐line pembrolizumab	16
Clinical characteristics and risk factors for in‐hospital mortality of lung cancer patients with COVID‐19: A multicenter, retrospective, cohort study	15
Ultrathin bronchoscope combined with virtual bronchoscopic navigation and endobronchial ultrasound for the diagnosis of peripheral pulmonary lesions with or without fluoroscopy: A randomized trial	15
Epidemiological landscape of esophageal cancer in Asia: Results from GLOBOCAN 2020	15
Efficacy of PD‐1/PD‐L1 inhibitors in patients with non‐small cell lung cancer and brain metastases: A real‐world retrospective study in China	15
The LungVision navigational platform for peripheral lung nodule biopsy and the added value of cryobiopsy	15
Inflammation‐nutritional markers of peripheral blood could predict survival in advanced non‐small‐cell lung cancer patients treated with PD‐1 inhibitors	15
Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small‐cell lung cancer patients treated with first‐line platinum‐containing chemotherapy	14
HSP90 inhibition overcomes EGFR amplification‐induced resistance to third‐generation EGFR‐TKIs	14
Autologous cytokine‐induced killer (CIK) cells enhance the clinical response to PD‐1 blocking antibodies in patients with advanced non‐small cell lung cancer: A preliminary study	14
Increased activation of cGAS‐STING pathway enhances radiosensitivity of non‐small cell lung cancer cells	14
Clinical‐radiological characteristics and intestinal microbiota in patients with pancreatic immune‐related adverse events	14

Construction of PEI‐EGFR‐PD‐L1‐siRNA dual functional nano‐vaccine and therapeutic efficacy evaluation for lung cancer	14
Feasibility investigation of near‐infrared fluorescence imaging with intravenous indocyanine green method in uniport video‐assisted thoracoscopic anatomical segmentectomy for identifying the intersegm	14
Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer harboring uncommon EGFR mutations: Real‐world data from Taiwan	14
Effectiveness of EGFR‐TKI rechallenge immediately after PD‐1 blockade failure	14
Evaluation of dual‐energy and perfusion CT parameters for diagnosing solitary pulmonary nodules	14
Estimated direct costs of non‐small cell lung cancer by stage at diagnosis and disease management phase: A whole‐disease model	14
Clinical outcomes and resource utilization after surgical resection with curative intent among patients with non‐small cell lung cancer treated with adjuvant therapies in a community oncology setting:	14
Comparison of adequacy between transbronchial lung cryobiopsy samples and endobronchial ultrasound‐guided transbronchial needle aspiration samples for next‐generation sequencing analysis	14
Autologous blood pleurodesis for the treatment of postoperative air leaks. A systematic review and meta‐analysis	14
Real‐world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non‐small cell lung cancer	14
Lung adenocarcinoma patients with KEAP1 mutation harboring low immune cell infiltration and low activity of immune environment	14
The landscape of small cell lung cancer metastases: Organ specificity and timing	14
Lung‐specific exosomes for co‐delivery of CD47 blockade and cisplatin for the treatment of non–small cell lung cancer	14
Circulating tumor cells (CTCs)/circulating tumor endothelial cells (CTECs) and their subtypes in small cell lung cancer: Predictors for response and prognosis	14
MiR‐423‐5p aggravates lung adenocarcinoma via targeting CADM1	14
Small cell transformation of non‐small cell lung cancer under immunotherapy: Case series and literature review	14
Efficacy of dacomitinib in patients with EGFR‐mutated NSCLC and brain metastases	14
GRP75‐mediated upregulation of HMGA1 stimulates stage I lung adenocarcinoma progression by activating JNK/c‐JUN signaling	14
Two cases of lung cancer with hemophagocytic lymphohistiocytosis caused by immune checkpoint inhibitors	13
Inhibitors of ABCB1 and ABCG2 overcame resistance to topoisomerase inhibitors in small cell lung cancer	13
Pembrolizumab provides long‐term survival benefits in advanced non‐small cell lung cancer: The 5‐year outcomes of the KEYNOTE‐024 trial	13
The airway microbiota of non‐small cell lung cancer patients and its relationship to tumor stage andEGFRgene mutation	13
Circ_0000520 contributes to triple‐negative breast cancer progression through mediating the miR‐1296/ZFX axis	13
Surgical perspective in neoadjuvant chemoimmunotherapy for stage II–III non‐small cell lung cancer	13
Circ_ZFR affects FABP7 expression to regulate breast cancer progression by acting as a sponge for miR‐223‐3p	13
Circular RNA circCPA4 promotes tumorigenesis by regulating miR‐214‐3p/TGIF2 in lung cancer	13
Circ_0069094 regulates malignant phenotype and paclitaxel resistance in breast cancer cells via targeting the miR‐136‐5p/YWHAZ axis	13
History and current situation of neoadjuvant treatment for locally advanced esophageal cancer	13
Efficacy and safety of anti‐PD‐1/PD‐L1 in combination with chemotherapy or not as first‐line treatment for advanced non‐small cell lung cancer: A systematic review and network me	13
Prognostic value of ferroptosis‐related genes in patients with lung adenocarcinoma	13
Transformation from adenocarcinoma to squamous cell lung carcinoma with MET amplification after lorlatinib resistance: A case report	13
Advances in study of the sequence of lung tumor biopsy and thermal ablation	12
CT‐guided microwave ablation in patients with lung metastases from breast cancer	12
Effect of physical manipulation pulmonary rehabilitation on lung cancer patients after thoracoscopic lobectomy	12
PD‐L1 and CD47 co‐expression predicts survival and enlightens future dual‐targeting immunotherapy in non‐small cell lung cancer	12
Tissue surface area and tumor cell count affect the success rate of the Oncomine Dx Target Test in the analysis of biopsy tissue samples	12
Prognostic effect of cachexia in patients with non‐small cell lung cancer receiving immune checkpoint inhibitors	12
A fully automated noncontrast CT 3‐D reconstruction algorithm enabled accurate anatomical demonstration for lung segmentectomy	12
The prognostic significance of tumor spread through air space in stage I lung adenocarcinoma	12
MiR‐192/NKRF axis confers lung cancer cell chemoresistance to cisplatin via the NF‐κB pathway	12
Reproducible abscopal effect in a patient with lung cancer who underwent whole‐brain irradiation and atezolizumab administration	12
Comparison of the analytical performance between the Oncomine Dx Target Test and a conventional single gene test for epidermal growth factor receptor mutati	12
ALK‐rearranged squamous cell carcinoma of the lung	12
MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC	12
The role of EGFR‐TKIs as adjuvant therapy in EGFR mutation‐positive early‐stage NSCLC: A meta‐analysis	12
Elevations of monocyte and neutrophils, and higher levels of granulocyte colony‐stimulating factor in peripheral blood in lung cancer patients	12
Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation	12
Pretreatment absolute lymphocyte count is an independent predictor for survival outcomes for esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy and pembrolizumab: A	11
Remarkable response of non‐small cell lung cancer to nintedanib treatment in a patient with idiopathic pulmonary fibrosis	11
Update on adjuvant therapy in completely resected NSCLC patients	11
Chaperone‐mediated autophagy affects tumor cell proliferation and cisplatin resistance in esophageal squamous cell carcinoma	11
Interstitial lung disease associated with capmatinib therapy in a patient with non‐small cell lung cancer harboring a skipping mutation of MET exon 14	11
Reconstruction of the trachea and carina: Surgical reconstruction, autologous tissue transplantation, allograft transplantation, and bioengineering	11
Risk factors for pneumonitis in patients with non‐small cell lung cancer treated with immune checkpoint inhibitors plus chemotherapy: A retrospective analysis	11
Efficacy and predictors of rechallenge with immune checkpoint inhibitors in non‐small cell lung cancer	11
Thymoma‐associated myasthenia gravis: Clinical features and predictive value of antiacetylcholine receptor antibodies in the risk of recurrence of thymoma	11
Remarkable response to pembrolizumab with platinum‐doublet in PD‐L1‐low pulmonary sarcomatoid carcinoma: A case report	11
Mubritinib enhanced the inhibiting function of cisplatin in lung cancer by interfering with mitochondrial function	11
Circulating tumor cells PD‐L1 expression detection and correlation of therapeutic efficacy of immune checkpoint inhibition in advanced non‐small‐cell lung cancer	11
Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma	11
Preoperative predictors of restoration in quality of life after surgery for lung cancer	11
Formation, contents, functions of exosomes and their potential in lung cancer diagnostics and therapeutics	11
Knockdown of circ‐RAD23B inhibits non‐small cell lung cancer progression via the miR‐142‐3p/MAP4K3 axis	11
Resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in non‐small cell lung cancer patients: A meta‐analysis	10
A cross‐sectional study of psychological burden in Chinese patients with pulmonary nodules: Prevalence and impact on the management of nodules	10
Intestinal flora characteristics of advanced non‐small cell lung cancer in China and their role in chemotherapy based on metagenomics: A prospective exploratory cohort study	10
miR‐493 by regulating of c‐Jun targets Wnt5a/PD‐L1‐inducing esophageal cancer cell development	10
Primary mediastinal large B cell lymphoma	10
Circ_0011292 knockdown mitigates progression and drug resistance in PTX‐resistant non‐small‐cell lung cancer cells by regulating miR‐433‐3p/CHEK1 axis	10
Predicting the efficacy of first‐line immunotherapy by combining cancer cachexia and tumor burden in advanced non‐small cell lung cancer	10
Noninvasive assessment of breast cancer molecular subtypes on multiparametric MRI using convolutional neural network with transfer learning	10
Robot‐assisted thymectomy in large anterior mediastinal tumors: A comparative study with video‐assisted thymectomy and open surgery	10
Lymphovascular invasion: A non‐sized T descriptor for stage IA non‐small cell lung cancer	10
Hexokinases II‐mediated glycolysis governs susceptibility to crizotinib in ALK‐positive non‐small cell lung cancer	10
A case of cytokine release syndrome accompanied with COVID‐19 infection during treatment with immune checkpoint inhibitors for non‐small cell lung cancer	10
Low baseline plasma PCSK9 level is associated with good clinical outcomes of immune checkpoint inhibitors in advanced non‐small cell lung cancer	10
HN1L promotes invasion and metastasis of the esophagogastric junction adenocarcinoma	10
Outcomes of salvage lung resections in advanced EGFR‐mutant lung adenocarcinomas under EGFR TKIs	10
Immune checkpoint inhibitors for first‐line treatment of advanced non‐small‐cell lung cancer: A systematic review and network meta‐analysis	10
Use of PD‐1 inhibitor tislelizumab in the treatment of advanced pulmonary sarcomatoid carcinoma: A case report	10

Efficacy of first‐line immune checkpoint inhibitors in patients with advanced NSCLC with KRAS, MET, FGFR, RET, <	10
Tumor LAG‐3 and NY‐ESO‐1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non‐small cell lung cancer	10
Glasgow Prognostic Score predicts chemotherapy‐triggered acute exacerbation‐interstitial lung disease in patients with non‐small cell lung cancer	10
Identification of circ_0058357 as a regulator in non‐small cell lung cancer cells resistant to cisplatin by miR‐361‐3p/ABCC1 axis	10
Impact of docetaxel plus ramucirumab in a second‐line setting after chemoimmunotherapy in patients with non‐small‐cell lung cancer: A retrospective study	10
Gut microbiota shed new light on the management of immune‐related adverse events	10
Management of chyle leakage after general thoracic surgery: Impact of thoracic duct embolization	10
Treatment patterns and outcomes of immunotherapy in extensive‐stage small‐cell lung cancer based on real‐world practice	10
Significance of tumor mutation burden and immune infiltration in thymic epithelial tumors	9
Zinc‐finger E‐box‐binding homeobox 1 (ZEB1) plays a crucial role in the maintenance of lung cancer stem cells resistant to gefitinib	9
Primary ciliated muconodular papillary tumor: A rare pulmonary disease and literature review of 65 cases	9
Concurrent use of anlotinib overcomes acquired resistance to EGFR‐TKI in patients with advanced EGFR‐mutant non‐small cell lung cancer	9
Association of thyroid transcription factor‐1 with the efficacy of immune‐checkpoint inhibitors in patients with advanced lung adenocarcinoma	9
Thymic epithelial tumors: Do we know all the prognostic factors?	9
Circ_0010235 facilitates lung cancer development and immune escape by regulating miR‐636/PDL1 axis	9
Learning curve of robotic portal lobectomy for pulmonary neoplasms: A prospective observational study	9
Co‐ablation versus cryoablation for the treatment of stage III–IV non‐small cell lung cancer: A prospective, noninferiority, randomized, controlled trial (RCT)	9
Recombinant human adenovirus type 5 (Oncorine) reverses resistance to immune checkpoint inhibitor in a patient with recurrent non‐small cell lung cancer: A case report	9
Susceptibility of lung cancer patients to COVID‐19: A review of the pandemic data from multiple nationalities	9
Simultaneous bilateral pulmonary resection via single‐utility port VATS for multiple pulmonary nodules: A single‐center experience of 16 cases	9
KIN17 promotes tumor metastasis by activating EMT signaling in luminal‐A breast cancer	9
A phase II study of anlotinib combined with etoposide and platinum‐based regimens in the first‐line treatment of extensive‐stage small cell lung cancer	9
Effect of prior immunotherapy on the efficacy of chemotherapy in advanced non‐small cell lung cancer: A retrospective study	9
Impact of coexistent preserved ratio impaired spirometry on the survival of patients with lung cancer: Analysis of data from the Korean Association for Lung Cancer Registry	9
Handling benign interlobar lymphadenopathy during thoracoscopic lobectomy	9
Comparison of the analytical performance of the Oncomine dx target test focusing on bronchoscopic biopsy forceps size in non‐small cell lung cancer	9
Prognostic impact of chronological age on efficacy of immune checkpoint inhibitors in non‐small‐cell lung cancer: Real‐world data from 86 173 patients	9
Primary pulmonary meningioma presenting as multiple lung nodules: A case report	9
Effect of cyclooxygenase inhibitor use on immunotherapy efficacy in non‐small cell lung cancer	9
Chinese expert consensus on the diagnosis and treatment of thymic epithelial tumors	9
Clinical outcomes of EGFR+/METamp+ vs. EGFR+/METamp‐ untreated patients with advanced non‐small cell lung cancer	9
Active cycle of breathing technique may reduce pulmonary complications after esophagectomy: A randomized clinical trial	9
Treatment with immune checkpoint inhibitors after EGFR‐TKIs in EGFR‐mutated lung cancer	9
Current status and perspectives of spread through air spaces in lung cancer	9
Significant difference in recurrence according to the proportion of high grade patterns in stage IA lung adenocarcinoma	9
A targeted siRNA‐loaded PDL1‐exosome and functional evaluation against lung cancer	9
Circulating tumor DNA predicts the outcome of chemotherapy in patients with lung cancer	9
RNF213 gene mutation in circulating tumor DNA detected by targeted next‐generation sequencing in the assisted discrimination of early‐stage lung cancer from pulmonary nodu	9
Sex differences in the characteristics and survival of patients with non‐small‐cell lung cancer: A retrospective analytical study based on real‐world clinical data of the Korean population	9
Long non‐coding RNA CCAT1 sponges miR‐490 to enhance cell proliferation and migration of non‐small cell lung cancer	9
Clinical impact of first‐line PD‐1 or PD‐L1 inhibitors combined with chemotherapy in extensive‐stage small cell lung cancer patients: A real‐world multicenter propensi	9
Impact of losing adipose tissue on outcomes from PD‐1/PD‐L1 inhibitor monotherapy in non‐small cell lung cancer	9
Glasgow prognostic score for prediction of chemotherapy‐triggered acute exacerbation interstitial lung disease in patients with small cell lung cancer	9
Diabetic ketoacidosis shortly after COVID‐19 vaccination in a non–small‐cell lung cancer patient receiving combination of PD‐1 and CTLA‐4 inhibitors: A case report	9
Functional inhibition of heat shock protein 70 by VER‐155008 suppresses pleural mesothelioma cell proliferation via an autophagy mechanism	9
Combination of nitrous oxide and the modified inflation‐deflation method for identifying the intersegmental plane in segmentectomy: A randomized controlled trial	8
Radiation recall pneumonitis after COVID‐19 vaccination	8
miRNA‐218‐5p increases cell sensitivity by inhibiting PRKDC activity in radiation‐resistant lung carcinoma cells	8
Cytokine release syndrome complicated with severe rashes induced by nivolumab plus ipilimumab therapy in a patient with non‐small cell lung cancer: A case report	8
PRKCB is relevant to prognosis of lung adenocarcinoma through methylation and immune infiltration	8
Diagnostic performance of dynamic contrast‐enhanced magnetic resonance imaging for breast cancer detection: An update meta‐analysis	8
Diagnostic efficacy of sentinel lymph node in breast cancer under percutaneous contrast‐enhanced ultrasound: An updated meta‐analysis	8
Proteomic profiling of extracellular vesicles and particles reveals the cellular response to cisplatin in NSCLC	8
Prognostic impact according to the proportion of the lepidic subtype in stage IA acinar‐predominant lung adenocarcinoma	8
Longitudinal changes in skeletal muscle mass in patients with advanced squamous cell lung cancer	8
Primary resistance to alectinib in a patient with STRN‐ALK‐positive non‐small cell lung cancer: A case report	8
Abnormal activation of NF‐κB and MAPK signaling pathways affect osimertinib resistance and influence the recruitment of myeloid‐derived suppressor cells to shape the immunosuppre	8
Esophageal cancer: Outcome and potential benefit of esophagectomy in elderly patients	8
miR‐92a‐3p promotes breast cancer proliferation by regulating the KLF2/BIRC5 axis	8
Curcumin suppresses lung cancer progression via circRUNX1 mediated miR‐760/RAB3D axis	8
PD‐0332991 combined with cisplatin inhibits nonsmall cell lung cancer and reversal of cisplatin resistance	8
The optimal therapy strategy for epidermal growth factor receptor‐mutated non‐small cell lung cancer patients with brain metastasis: A real‐world study from Taiwan	8
Long‐term remission of small cell lung cancer after reactivation of tuberculosis following immune‐checkpoint blockade: A case report	8
Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patients	8
Mutation profile and immunoscore signature in thymic carcinomas: An exploratory study and review of the literature	8
Scutellarin improves the radiosensitivity of non‐small cell lung cancer cells to iodine‐125 seeds via downregulating the AKT/mTOR pathway	8
CircRNA PRH1‐PRR4 stimulates RAB3D to regulate the malignant progression of NSCLC by sponging miR‐877‐5p	8
SMARCA4‐deficient undifferentiated tumor that responded to chemotherapy in combination with immune checkpoint inhibitors: A case report	8
Diagnosis of malignant pleural disease: Ultrasound as “a detective probe”	8
Chemoradiation followed by adjuvant durvalumab in stage III non–small cell lung cancer: Real‐world comparison of treatment outcomes to historical controls treated with chemoradia	8
Precision targeted therapy for EGFR mutation‐positive NSCLC: Dilemmas and coping strategies	8
Sarcopenia as a predictor of initial administration dose of afatinib in patients with advanced non‐small cell lung cancer	8
Salvage surgery following downstaging of advanced non‐small cell lung cancer by targeted therapy	8
Endostar (rh‐endostatin) improves efficacy of concurrent chemoradiotherapy for locally advanced non‐small cell lung cancer: A systematic review and meta‐analysis	8
LncRNA and mRNA expression associated with myasthenia gravis in patients with thymoma	8
Host immune‐inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD‐L1 ≥50% metastatic non‐small cell lung cancer and poor performance status receiving	8
Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non‐small‐cell lung cancer: A multicenter retrospective trial	8
PD‐L1 expressed from tumor cells promotes tumor growth and invasion in lung cancer via modulating TGF‐β1/SMAD4 expression	8
The effect of metformin or dipeptidyl peptidase 4 inhibitors on clinical outcomes in metastatic non‐small cell lung cancer treated with immune checkpoint inhibitors	8
Distinct clinicopathological features of pulmonary primary angiomatoid fibrous histiocytoma: A report of four new cases and review of the literature	8
Multiple primary pulmonary meningioma: A case report and literature review	8
Postoperative venous thromboembolism after surgery for stage IA non‐small‐cell lung cancer: A single‐center, prospective cohort study	8
Third‐generation EGFR inhibitor HS‐10296 in combination with famitinib, a multi‐targeted tyrosine kinase inhibitor, exerts synergistic antitumor effects through enhanced inhibiti	8
Efficacy and safety of EBUS‐TBNA under conscious sedation with meperidine and midazolam	8
Safety and efficacy of microwave ablation for lung cancer adjacent to the interlobar fissure	8
Update on therapeutic strategy for esophageal anastomotic leak: A systematic literature review	8
Safety and efficacy of endobronchial ultrasound‐guided transbronchial needle aspiration (EBUS‐TBNA) for patients aged 80 years and older	8
Prognostic effect of perineural invasion in surgically treated esophageal squamous cell carcinoma	8
Upregulation of SIX4 indicates poor clinical outcome and promotes tumor growth and cell metastasis in esophageal squamous cell carcinoma	8
Effects of periodontitis on postoperative pneumonia in patients with lung and esophageal cancer	8
ASCL1 and DLL3 expressions and their clinicopathological implications in surgically resected pure small cell lung cancer: A study of 247 cases from the National Cancer Cente	8
Diagnostic performance of SHOX2 promoter methylation as biomarker for lung cancer identification: A meta‐analysis update	8
Patient prognostic scores and association with survival improvement offered by postoperative radiotherapy for resected IIIA/N2 non‐small cell lung cancer: A population‐based stud	8
Tumor‐educated leukocytes mRNA as a diagnostic biomarker for non‐small cell lung cancer	8
Rare case of apatinib acquired resistance induced by point mutation of WRN p.V697F through activation of the PI3K/AKT apoptosis‐inhibiting pathwa	8